TOP TEN perturbations for 38670_at (Homo sapiens)

Organism: Homo sapiens
Gene: 38670_at
Selected probe(set): 211678_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 38670_at (211678_s_at) across 6674 perturbations tested by GENEVESTIGATOR:

kidney transplantation study 16 (2 week) / normal natural killer cell (CD56+) sample

Relative Expression (log2-ratio):-2.394823
Number of Samples:3 / 3
Experimental kidney transplantation study 16 (2 week)
CD56+ natural killer cell samples derived from kidney transplant patients 2 weeks post-transplantation. Samples were collected 2 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal natural killer cell (CD56+) sample
CD56+ natural killer cell samples derived from healthy control subjects.

R547 study 1 (24h) / vehicle (DMSO) treated DU145 cell sample

Relative Expression (log2-ratio):-2.1038256
Number of Samples:2 / 4
Experimental R547 study 1 (24h)
Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 24 hours at a 3xIC90 concentration of 5.1 μmol/L. ATC code:---
Control vehicle (DMSO) treated DU145 cell sample
Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 24 hours.

pediatric septic shock study 3 (toddler; subclass A) / pediatric septic shock study 3 (toddler)

Relative Expression (log2-ratio):-1.8411894
Number of Samples:4 / 23
Experimental pediatric septic shock study 3 (toddler; subclass A)
Whole blood samples obtained from toddlers (2 – 5 years) with septic shock subclass A. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. One child did not survive. The subclass A was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients in subclass A (when all age groups were pooled) had a significantly higher illness severity level (PRISM III score = 20.5, intra-quartile range (IQR) 12.5 – 32.5), a greater degree of organ failure – maximum number of organ failures 3 (IQR 3 - 4), and a higher mortality rate, a significantly higher incidence of documented Gram-positive bacterial infection and were significantly younger compared with other subclasses.
Control pediatric septic shock study 3 (toddler)
Whole blood obtained from toddlers (2 – 5 years) with septic shock. The samples were obtained within 24 hours of admission to the pediatric intensive care unit (day 1). Two children did not survive.

pediatric septic shock study 3 (toddler; subclass A) / normal blood sample (toddler)

Relative Expression (log2-ratio):-1.8392076
Number of Samples:4 / 18
Experimental pediatric septic shock study 3 (toddler; subclass A)
Whole blood samples obtained from toddlers (2 – 5 years) with septic shock subclass A. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. One child did not survive. The subclass A was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients in subclass A (when all age groups were pooled) had a significantly higher illness severity level (PRISM III score = 20.5, intra-quartile range (IQR) 12.5 – 32.5), a greater degree of organ failure – maximum number of organ failures 3 (IQR 3 - 4), and a higher mortality rate, a significantly higher incidence of documented Gram-positive bacterial infection and were significantly younger compared with other subclasses.
Control normal blood sample (toddler)
Whole blood samples from toddlers (2 – 5 years). Children who had a recent febrile illness (within 2 weeks), who recently used anti-inflammatory medications (within 2 weeks) or who had any history of chronic or acute disease associated with inflammation were excluded from the study.

pediatric septic shock study 3 (infant; subclass A) / normal blood sample (infant)

Relative Expression (log2-ratio):-1.7464066
Number of Samples:8 / 17
Experimental pediatric septic shock study 3 (infant; subclass A)
Whole blood samples obtained from infants (1 month – 1 year) with septic shock subclass A. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. Two children did not survive. The subclass A was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients in subclass A (when all age groups were pooled) had a significantly higher illness severity level (PRISM III score = 20.5, intra-quartile range (IQR) 12.5 – 32.5), a greater degree of organ failure – maximum number of organ failures 3 (IQR 3 - 4), and a higher mortality rate, a significantly higher incidence of documented Gram-positive bacterial infection and were significantly younger compared with other subclasses.
Control normal blood sample (infant)
Whole blood samples from infants (1 month – 1 year). Children who had a recent febrile illness (within 2 weeks), who recently used anti-inflammatory medications (within 2 weeks) or who had any history of chronic or acute disease associated with inflammation were excluded from the study.

TNF-ɑ study 16 (12h) / rheumatoid arthritis study 10

Relative Expression (log2-ratio):1.7358646
Number of Samples:3 / 6
Experimental TNF-ɑ study 16 (12h)
Synovial fibroblast samples isolated from affected knee of patients with rheumatoid factor positive rheumatoid arthritis (RA) were stimulated by 10 ng/ml of TNF-ɑ in serum-free DMEM for 12 hours. Synovial fibroblasts were isolated from surgically obtained synovial membrane by trypsin/collagenase digestion, followed by negative purification using CD-14 Dynabeads® M-450. Before the TNF-ɑ stimulation, fibroblasts were cultured for four passages in DMEM medium supplemented with antibiotics and 10% FCS. The RA was classified according to the criteria of the American College of Rheumatology. Average duration of RA: 11.5 ± 0.5 years. Patients were receiving non-steroidal antiinflammatory drugs. CRP: 38.1 ± 7.2 mg/l.
Control rheumatoid arthritis study 10
Synovial fibroblast samples isolated from affected knee of patients with rheumatoid factor positive rheumatoid arthritis (RA), classified according to the criteria of the American College of Rheumatology. Average duration of RA: 11.5 ± 0.5 years. Patients were receiving non-steroidal antiinflammatory drugs. CRP: 38.1 ± 7.2 mg/l. Synovial fibroblasts were isolated from surgically obtained synovial membrane by trypsin/collagenase digestion, followed by negative purification using CD-14 Dynabeads® M-450. The fibroblasts were than cultured for four passages in DMEM medium supplemented with antibiotics and 10% FCS. Prior RNA isolation, the fibroblasts were washed in serum free DMEM.

cyclophosphamide study 6 (8155 uM; hES-Heps) / vehicle (DMSO) treated hES-Heps cell sample

Relative Expression (log2-ratio):1.7183952
Number of Samples:3 / 8
Experimental cyclophosphamide study 6 (8155 uM; hES-Heps)
hES-Heps cells exposed to 8155 uM cyclophosphamide (dissolved in 0.5% v/v DMSO) for 72 hours. Chemical was added at day 22 of differentiation. Cells were treated with the IC10 determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test (number of replicates, n = 3). ATC code:
Control vehicle (DMSO) treated hES-Heps cell sample
hES-Heps cells treated with vehicle (DMSO 0.5% v/v) for 72 hours. Vehicle was added at day 22 of differentiation.

T. cruzi study 1 (BJ; 24h; top) / mock infected foreskin fibroblast (BJ) sample (24h; top)

Relative Expression (log2-ratio):1.7066374
Number of Samples:2 / 2
Experimental T. cruzi study 1 (BJ; 24h; top)
Foreskin fibroblast (BJ) cells grown in the transwell top, bathed with media from the BJ cells infected with Trypanosoma cruzi trypomastigotes for 2 hours (10exp8/ml) and harvested 24 hours post infection. In the transwell setup, cells in the top chamber served as reporters for the effect of all difusible factors secreted by parasite-infected cells in the bottom chamber. Cells were maintained in DMEM supplemented with 10% fetal bovine serum (FBS), 2 mM glutamine, 100 U/ml penicillin and 100 ug/ml streptomycin.
Control mock infected foreskin fibroblast (BJ) sample (24h; top)
Foreskin fibroblast (BJ) cells grown in the transwell top, bathed with media from the mock-infected bottom BJ cells, harvested 24 hours post mock infection with 2% FBS medium. In the transwell setup, cells in the top chamber served as reporters for the effect of all difusible factors secreted by mock-infected cells in the bottom chamber. Cells were maintained in DMEM supplemented with 10% fetal bovine serum (FBS), 2 mM glutamine, 100 U/ml penicillin and 100 ug/ml streptomycin.

pediatric septic shock study 3 (infant; subclass A) / pediatric septic shock study 3 (infant)

Relative Expression (log2-ratio):-1.7032986
Number of Samples:8 / 30
Experimental pediatric septic shock study 3 (infant; subclass A)
Whole blood samples obtained from infants (1 month – 1 year) with septic shock subclass A. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. Two children did not survive. The subclass A was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients in subclass A (when all age groups were pooled) had a significantly higher illness severity level (PRISM III score = 20.5, intra-quartile range (IQR) 12.5 – 32.5), a greater degree of organ failure – maximum number of organ failures 3 (IQR 3 - 4), and a higher mortality rate, a significantly higher incidence of documented Gram-positive bacterial infection and were significantly younger compared with other subclasses.
Control pediatric septic shock study 3 (infant)
Whole blood obtained from infants (1 month – 1 year) with septic shock. The samples were obtained within 24 hours of admission to the pediatric intensive care unit (day 1). Five children did not survive.

atopic dermatitis study 21 (lesional; whole skin) / normal skin tissue

Relative Expression (log2-ratio):-1.6845789
Number of Samples:5 / 6
Experimental atopic dermatitis study 21 (lesional; whole skin)
Lesional full thickness skin samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %.
Control normal skin tissue
Full thickness skin samples isolated from healthy subjects by laser capture microdissection.